TY - JOUR
T1 - Case fatality rate of cancer patients with COVID-19 in a New York Hospital system
AU - Mehta, Vikas
AU - Goel, Sanjay
AU - Kabarriti, Rafi
AU - Cole, Daniel
AU - Goldfinger, Mendel
AU - Acuna-Villaorduna, Ana
AU - Pradhan, Kith
AU - Thota, Raja
AU - Reissman, Stan
AU - Sparano, Joseph A.
AU - Gartrell, Benjamin A.
AU - Smith, Richard V.
AU - Ohri, Nitin
AU - Garg, Madhur
AU - Racine, Andrew D.
AU - Kalnicki, Shalom
AU - Perez-Soler, Roman
AU - Halmos, Balazs
AU - Verma, Amit
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/7
Y1 - 2020/7
N2 - Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due to underlying malignancy, treatment-related immu-nosuppression, or increased comorbidities. A total of 218 COVID-19–positive patients from March 18, 2020, to April 8, 2020, with a malignant diagnosis were identified. A total of 61 (28%) patients with cancer died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. Six of 11 (55%) patients with lung cancer died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comor-bidities, need for ICU support, and elevated levels of D-dimer, lactate dehydrogenase, and lactate in multivariate analysis. Age-adjusted CFRs in patients with cancer compared with noncancer patients at our institution and New York City reported a significant increase in case fatality for patients with can-cer. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. SIGNIFICANCE: COVID-19 in patients with cancer is associated with a significantly increased risk of case fatality, suggesting the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population.
AB - Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due to underlying malignancy, treatment-related immu-nosuppression, or increased comorbidities. A total of 218 COVID-19–positive patients from March 18, 2020, to April 8, 2020, with a malignant diagnosis were identified. A total of 61 (28%) patients with cancer died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. Six of 11 (55%) patients with lung cancer died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comor-bidities, need for ICU support, and elevated levels of D-dimer, lactate dehydrogenase, and lactate in multivariate analysis. Age-adjusted CFRs in patients with cancer compared with noncancer patients at our institution and New York City reported a significant increase in case fatality for patients with can-cer. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. SIGNIFICANCE: COVID-19 in patients with cancer is associated with a significantly increased risk of case fatality, suggesting the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population.
UR - http://www.scopus.com/inward/record.url?scp=85087469794&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-20-0516
DO - 10.1158/2159-8290.CD-20-0516
M3 - Article
C2 - 32357994
AN - SCOPUS:85087469794
SN - 2159-8274
VL - 10
SP - 935
EP - 941
JO - Cancer Discovery
JF - Cancer Discovery
IS - 7
ER -